171 related articles for article (PubMed ID: 37897876)
21. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.
Valverde-Monge M; Sánchez-Carrasco P; Betancor D; Barroso B; Rodrigo-Muñoz JM; Mahillo-Fernández I; Arismendi E; Bobolea I; Cárdaba B; Cruz MJ; Del Pozo V; Domínguez-Ortega J; González-Barcala FJ; Olaguibel JM; Luna-Porta JA; Martínez-Rivera C; Mullol J; Muñoz X; Peleteiro-Pedraza L; Picado Valles C; Plaza V; Quirce S; Rial MJ; Soto-Retes L; Valero A; Sastre J
Arch Bronconeumol; 2024 Jan; 60(1):23-32. PubMed ID: 38042707
[TBL] [Abstract][Full Text] [Related]
22. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
23. Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response.
Abbas F; Georas S; Cai X; Khurana S
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):655-660.e1. PubMed ID: 34481992
[TBL] [Abstract][Full Text] [Related]
24. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
25. Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study.
Rojo-Tolosa S; González-Gutiérrez MV; Jiménez-Gálvez G; Sánchez-Martínez JA; Pineda-Lancheros LE; Gálvez-Navas JM; Jiménez-Morales A; Pérez-Ramírez C; Morales-García C
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768331
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
27. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry.
Chen W; Tran TN; Sadatsafavi M; Murray R; Wong NCB; Ali N; Ariti C; Bulathsinhala L; Gil EG; FitzGerald JM; Alacqua M; Al-Ahmad M; Altraja A; Al-Lehebi R; Bhutani M; Bjermer L; Bjerrum AS; Bourdin A; von Bülow A; Busby J; Canonica GW; Carter V; Christoff GC; Cosio BG; Costello RW; Fonseca JA; Gibson PG; Yoo KH; Heaney LG; Heffler E; Hew M; Hilberg O; Hoyte F; Iwanaga T; Jackson DJ; Jones RC; Koh MS; Kuna P; Larenas-Linnemann D; Lehmann S; Lehtimäki L; Lyu J; Mahboub B; Maspero J; Menzies-Gow AN; Newell A; Sirena C; Papadopoulos NG; Papaioannou AI; Perez-de-Llano L; Perng Steve DW; Peters M; Pfeffer PE; Porsbjerg CM; Popov TA; Rhee CK; Salvi S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Ra SW; Wang E; Wechsler ME; Price DB
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2732-2747. PubMed ID: 37301430
[TBL] [Abstract][Full Text] [Related]
28. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Pavord ID; Bel EH; Bourdin A; Chan R; Han JK; Keene ON; Liu MC; Martin N; Papi A; Roufosse F; Steinfeld J; Wechsler ME; Yancey SW
Allergy; 2022 Mar; 77(3):778-797. PubMed ID: 34402066
[TBL] [Abstract][Full Text] [Related]
29. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
31. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
[TBL] [Abstract][Full Text] [Related]
32. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
[TBL] [Abstract][Full Text] [Related]
33. Real-Life Experience of Biologic Treatment for Asthma on Chronic Rhinosinusitis: A Finnish Cohort.
Lyly A; Genberg E; Kauppi P; Virkkula P; Lee SE; Laidlaw TM; Toppila-Salmi S; Lundberg M
Int Arch Allergy Immunol; 2023; 184(2):149-160. PubMed ID: 36349770
[TBL] [Abstract][Full Text] [Related]
34. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
[TBL] [Abstract][Full Text] [Related]
35. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
36. Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?
Carson LN; Pradhan A; Subramanian D
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34326107
[TBL] [Abstract][Full Text] [Related]
37. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
38. Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.
Bakakos A; Rovina N; Loukides S; Bakakos P
Expert Opin Biol Ther; 2022 Jul; 22(7):855-870. PubMed ID: 35712995
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Real-World Escalation to Biologics in US Patients With Asthma.
Bender B; Oppenheimer J; George M; Brown R; Patel A; Hill T; Boe A; Mayen Herrera E; Dotiwala Z; Casciano J; Bernstein JA
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2941-2948. PubMed ID: 35931363
[TBL] [Abstract][Full Text] [Related]
40. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
